Business Wire

PCI Pharma Services Announces the Acquisition of Bellwyck Pharma Services to Expand Global Clinical Trial Services into Canada and Continental Europe

Share

PCI Pharma Services (PCI), a leading pharmaceutical and biopharmaceutical global supply chain solutions provider, today announced the acquisition of Bellwyck Pharma Services (Bellwyck), headquartered in Toronto, Canada. With 25 years of experience, Bellwyck is a leader in primary and secondary packaging and labeling for clinical trial and commercial drug markets. The acquisition will add four GMP-compliant facilities to the PCI network in the U.S., Germany and Canada. With Canada and Germany ranked third and fourth in the world for total number of clinical trials, respectively,1 this acquisition greatly enhances the global reach of PCI’s services in key markets.

“We are thrilled to welcome the Bellwyck team into the PCI family,” said Salim Haffar, chief executive officer, PCI Pharma Services. “Their passion for patients, talented team and innovative approach to client challenges is perfectly aligned to our purpose and global strategy as PCI strives to be the bridge between life-changing therapies and patients around the world. We are particularly excited that this acquisition will expand our clinical business worldwide and provide our clients with access to sites in continental Europe and Canada, in addition to our existing facilities.”

Bellwyck’s clinical and commercial supply chain solutions mirror PCI’s existing core capabilities including extensive clinical trial packaging, labeling and logistics for Phase I-IV studies as well as full-service commercial packaging. With the addition of Bellwyck, PCI will now feature 25 GMP facilities across North America, Europe, and Asia-Pacific, employing over 3,700 highly trained associates.

“We are delighted that Bellwyck is joining the PCI team and anticipate a seamless integration for our employees and clients,” said Jeff Sziklai, chief executive officer, Bellwyck Pharma Services. “We have a shared focus on innovation, quality, exceptional service and our employees. Joining forces with a global industry leader, such as PCI, is a great step forward for Bellwyck. We look forward to helping accelerate the global growth of PCI’s clinical business, leveraging our reputation for innovative, customized clinical trial solutions for our clients.”

The acquisition of Bellwyck to establish a presence in Canada and Germany further underscores PCI’s global strategy and commitment to be the partner of choice to meet the market needs of its clients. The addition of Bellwyck will mark PCI’s third acquisition outside of the U.S. in three years, demonstrating PCI’s continued commitment to growth, geographic expansion and serving patients across the world.

PCI, headquartered in Philadelphia, PA, is principally owned by Partners Group on behalf of its clients, with partner investors Thomas H. Lee Partners and Frazier Healthcare.

Bellwyck engaged PricewaterhouseCoopers Corporate Finance Inc. as their financial advisor on this transaction.

_____________________
1 ClinicalTrials.gov Web site. Search of All Trials. Bethesda (MD): National Library of Medicine (US). Available: https://clinicaltrials.gov/ct2/results/map. Accessed 2020 January 27.

About PCI Pharma Services

The global healthcare industry trusts PCI for the drug development solutions that increase their products’ speed to market and opportunities for commercial success. Only PCI brings the proven experience that comes with more than 50 successful product launches a year and over five decades in the healthcare business. Leading technology and continued investment enable us to address global development needs throughout the product life cycle — from Phase I Clinical trials through commercialization and ongoing supply. Our clients view us as an extension of their business and a collaborative partner, with the shared goal of improving patients’ lives. For more information, please visit www.pciservices.com or follow us on Twitter at @PCI_Social.

Contact information

Nathan Molinari, WE Communications
nmolinari@we-worldwide.com / (212) 551-4860

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

SwitchDin’s Technology Selected for World-First Project to Increase Solar Hosting Capacity for Electricity Distribution Networks1.10.2020 22:00:00 CESTPress release

SwitchDin, an Australian energy management software company, has been retained by distribution networks, SA Power Networks and AusNet Services, to provide a global-first solution that will allow networks to create flexible solar export limits to accommodate the growth of rooftop solar photovoltaic (PV) systems that are connected to the grid. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201001005065/en/ SwitchDin CEO Dr Andrew Mears with SwitchDin Droplet controller (Photo: Business Wire) The installation of PV systems is growing at a rate of more than 200,000 each year in Australia’s National Electricity Market (NEM), and distribution networks are reaching the limit of their ability to host rooftop solar in some areas. This flexible export capability will allow SA Power Networks and AusNet Services to offer an alternative to the strict export limits currently required to address these challenges, increasing the penetration

Conrad Energy Acquires Viridis Power to Create the Largest Flexible Generation Platform in the UK1.10.2020 20:00:00 CESTPress release

Conrad Energy, a portfolio company of I Squared Capital and an independent power producer focused on flexible power generation, battery storage and energy management services for network and commercial customers, today announces a significant acceleration in its plans to support the UK energy transition. Conrad Energy has agreed to acquire Viridis Power, more than doubling its share of flexible generation for the UK power market, and bringing its operational portfolio to over 440MW at 28 sites across the UK and equivalent to the average hourly electricity needs of one million homes. The acquisition further strengthens the power generation, trading and operational capabilities of Conrad Energy, which specialises in innovative energy solutions that provide critical grid support. Conrad is already providing commercial customers with solutions for their energy needs, including flexible generators, storage and solar. This support will be critical as the UK integrates more renewable sources

EasyCOV, the Virological Saliva Test for COVID19 Confirms Its Excellent Results: a Sensitivity of 88% and a Specificity of 99% in 40 Min1.10.2020 18:23:00 CESTPress release

EasyCOV, a virological saliva detection test for COVID19, has shown a sensitivity of 88% and a specificity 99% during a clinical trial performed at the testing center operated by the teaching hospital of Montpellier. The test relies on an optimized thermal protocol that provides the results in 40 minutes. EasyCOV, developed by SkillCell in collaboration with the CNRS (French National Center for Scientific Research), is a saliva test that can be run in the field and that provides results in the form of a change of color in no more than 40 minutes. Performed by a healthcare professional, the test requires the collection of 200 microliters of saliva, approximately 4 drops, from under the patient’s tongue. The sample is heated successively in two tubes using the nomadic heating device EasyVID (developed and produced by TRONICO, sister company of SkillCell). A test turning bright yellow indicates that the virus has been detected while an orange test is negative. A double-blind clinical tria

Ascend Performance Materials Announces Global Price Increase for All Vydyne® Brand Polymers, Fibers and Compounds1.10.2020 16:00:00 CESTPress release

Ascend Performance Materials announced today a global price increase for all of its Vydyne® polymers, fibers and compounds. The price increase takes effect October 15, 2020, and includes the following price changes: Materials Geography Price Increases Terms Vydyne® (PA 66) polymers, fibers and compounds North America $220/MT As contracts allow Non-contract business – price determined on an order-by-order basis Vydyne® (PA 66) polymers, fibers and compounds Asia $300/MT As contracts allow Non-contract business – price determined on an order-by-order basis Vydyne® (PA 66) polymers, fibers and compounds Europe €200/MT As contracts allow Non-contract business – price determined on an order-by-order basis Customers should contact their local sales representative for additional information. About Ascend Performance Materials Ascend Performance Materials makes high-performance materials for everyday essentials and new technologies. Our focus is on improving quality of life and inspiring a bet

Andersen Global Adds SAGIS LP in Anguilla to Its Caribbean Platform1.10.2020 15:30:00 CESTPress release

Andersen Global bolsters its Caribbean platform through a Collaboration Agreement with full-service law firm SAGIS LP in Anguilla. In a span of three months, Andersen Global has significantly expanded its footprint throughout the region and will focus on providing additional coverage over the course of the next 18 to 24 months. Established in 2018 by four Partners, SAGIS LP provides its clients with a variety of legal services, including corporate, commercial, banking and finance, intellectual property and real estate. Additionally, the Firm’s team of lawyers are widely recognized within Chambers Global and World Trademark Review. Partner Kenneth G. Porter said, “We have been focused on delivering quality client solutions through our strategic thinking and have an in-depth understanding of our clients’ unique legal needs. Collaborating with Andersen Global positions us to meet our goal of expanding and providing more robust services, while being the firm of choice in Anguilla for local

Shionogi Announces Publication of a New Systematic Review in CHEST Highlighting the Importance of Early, Appropriate Therapy to Improve Meaningful Outcomes Like Mortality in Patients With Severe Bacterial Infections1.10.2020 15:14:00 CESTPress release

Shionogi B.V., the European subsidiary of Shionogi & Co., Ltd. (Head Office: Osaka, Japan; President & CEO: Isao Teshirogi, Ph.D.; hereafter "Shionogi") today announce the publication of a new systematic review in CHEST Journal, funded by Shionogi B.V, examining the effect of delayed appropriate antibiotic therapy on the outcomes of patients with severe bacterial infections.1 The review was carried out to characterise the impact of time to effective therapy for antimicrobials and guide treatment decisions to optimise prompt appropriate antibiotic therapy for patients most at risk. The study found that mortality was significantly lower in patients receiving appropriate therapy without delay compared with those experiencing delay.1 Severe bacterial infections requiring in-hospital treatment are associated with considerable mortality, morbidity and healthcare costs. Physicians must often initiate antibiotic therapy before the pathogen causing the infection and its drug-resistance profile

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom